Greenwich Lifesciences Cash And Equivalents vs. Current Valuation

GLSI Stock  USD 13.85  0.24  1.70%   
Based on Greenwich Lifesciences' profitability indicators, Greenwich Lifesciences may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Greenwich Lifesciences' ability to earn profits and add value for shareholders. As of now, Greenwich Lifesciences' Cash Per Share is increasing as compared to previous years. The Greenwich Lifesciences' current Price Book Value Ratio is estimated to increase to 21.18, while Book Value Per Share is projected to decrease to 0.47.
For Greenwich Lifesciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Greenwich Lifesciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Greenwich Lifesciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Greenwich Lifesciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Greenwich Lifesciences over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.81)
Return On Assets
(0.72)
Return On Equity
(1.24)
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Greenwich Lifesciences Current Valuation vs. Cash And Equivalents Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Greenwich Lifesciences's current stock value. Our valuation model uses many indicators to compare Greenwich Lifesciences value to that of its competitors to determine the firm's financial worth.
Greenwich Lifesciences is rated # 3 in cash and equivalents category among its peers. It is rated as one of the top companies in current valuation category among its peers reporting about  12.19  of Current Valuation per Cash And Equivalents. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Greenwich Lifesciences' earnings, one of the primary drivers of an investment's value.

Greenwich Current Valuation vs. Cash And Equivalents

Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Greenwich Lifesciences

Cash

 = 

Bank Deposits

+

Liquidities

 = 
15.64 M
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Greenwich Lifesciences

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
190.69 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Greenwich Current Valuation vs Competition

Greenwich Lifesciences is rated as one of the top companies in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 485.2 Million. Greenwich Lifesciences totals roughly 190.69 Million in current valuation claiming about 39% of equities under Health Care industry.

Greenwich Lifesciences Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Greenwich Lifesciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Greenwich Lifesciences will eventually generate negative long term returns. The profitability progress is the general direction of Greenwich Lifesciences' change in net profit over the period of time. It can combine multiple indicators of Greenwich Lifesciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-9.3 M-8.9 M
Net Loss-8.9 M-8.5 M
Income Before Tax-8.9 M-8.4 M
Net Loss-4.1 M-4.3 M
Net Loss-8.9 M-8.4 M
Total Other Income Expense Net436.1 K457.9 K
Income Tax Expense(2.00)(2.10)
Net Interest Income450.9 K473.5 K
Interest Income450.9 K473.5 K
Non Operating Income Net Other31.5 K33 K
Change To Netincome759.7 K475.3 K
Net Loss(0.69)(0.73)
Income Quality 0.73  0.38 
Net Income Per E B T 1.12  1.09 

Greenwich Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Greenwich Lifesciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Greenwich Lifesciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Greenwich Lifesciences' important profitability drivers and their relationship over time.

Use Greenwich Lifesciences in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Greenwich Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Greenwich Lifesciences will appreciate offsetting losses from the drop in the long position's value.

Greenwich Lifesciences Pair Trading

Greenwich Lifesciences Pair Trading Analysis

The ability to find closely correlated positions to Greenwich Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Greenwich Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Greenwich Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Greenwich Lifesciences to buy it.
The correlation of Greenwich Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Greenwich Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Greenwich Lifesciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Greenwich Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Greenwich Lifesciences position

In addition to having Greenwich Lifesciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Construction Materials Thematic Idea Now

Construction Materials
Construction Materials Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction Materials theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Materials Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:
Check out Risk vs Return Analysis.
For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
To fully project Greenwich Lifesciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Greenwich Lifesciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Greenwich Lifesciences' income statement, its balance sheet, and the statement of cash flows.
Potential Greenwich Lifesciences investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Greenwich Lifesciences investors may work on each financial statement separately, they are all related. The changes in Greenwich Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Greenwich Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.